Chemistry:EGX-A

From HandWiki

EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders.[1][2][3] It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents.[3] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences.[1][2] As of January 2024, it is in the preclinical research stage of development.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 "EGX A - AdisInsight". https://adisinsight.springer.com/drugs/800076204. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on EGX-A with Synapse". 25 January 2025. https://synapse.patsnap.com/drug/214dea83744c4d73b2864485779460e8. 
  3. ↑ 3.0 3.1 "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology 48 (Suppl 1): 211–354 (275–275). December 2023. doi:10.1038/s41386-023-01756-4. PMID 38040810. PMC 10729596. https://ir.atai.life/static-files/d589b5ff-b604-4321-925e-3f01fb7f7911. 


Template:Psychedelics




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EGX-A&oldid=4027285"